Alexander Hindenburg
Winthrop-University Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Alexander Hindenburg.
Frontiers in Oncology | 2013
Monique Chang; Jason Suh; Vatsala Kirtani; Andrei Dobrescu; J.A. Haas; Steven M. Zeldis; Steven Shayani; Alexander Hindenburg
Background and Objective: Radiation therapy (RT) is part of standard adjuvant treatment for breast cancer. Earlier studies demonstrated increased cardiac morbidity and mortality from this. Coronary Calcium scanning utilizing Multidetector Computed Tomography (MDCT) can detect early atherosclerosis in coronary arteries by identifying the amount of calcifications. In our study we employed these tools to detect occult atherosclerosis at least 5 years following breast RT. Methods: We evaluated 20 asymptomatic patients, <60 years old, treated with RT at least 5 years prior to enrollment. Nine received RT to the left and 11 to the right chest wall. The median interval between RT and calcium scan was 8 years. All patients were treated with external beam RT using tangential technique. All patients underwent MDCT to compute volumetric and Agatston calcium scores of the coronary arteries and the aorta. Results: Eleven patients had RT to the right chest wall, and eight had a calcium score of 0, while two had minimally elevated scores and one patient had a significantly elevated score. Meanwhile nine patients had RT to the left chest wall, and seven had a calcium score of 0. None had significantly elevated scores. In the aorta, 11 of 20 patients had a score of 0, while 8 of 20 had minimally elevated scores. Conclusion: In contrast to studies demonstrating increased cardiovascular morbidity, our pilot study did not detect significant occult atherosclerosis using MDCT of the coronaries and aorta of patients assessed five or more years following radiation for treatment of breast cancer.
Cancer Chemotherapy and Pharmacology | 1991
James E. Gervasoni; Robert N. Taub; Michelle Rosado; Sindu Krishna; Valerie J. Stewart; Daniel M. Knowles; Kapil N. Bhalla; Douglas D. Ross; Michael A. Baker; Jose Lutzky; Alexander Hindenburg
SummaryThe glycoproteins on the surface of HL-60/S wild-type, drug-sensitive human leukemia cells and HL-60/AR anthracycline-resistant cells which do not overexpress the P-glycoprotein, were characterized by labeling with [35S]-methionine, NaB[3H4], phosphorus 32, or sodium iodide I 125. HL-60/S and HL-60/AR cell lysates and membrane fractions tagged with [35S]-methionine or phosphorus 32 showed no significant differences in their protein patterns as analyzed by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and by autoradiography. HL-60/S cells labeled with NaB[3H4] yielded glycoproteins that were smeared predominantly in the molecular-weight range of 210,000 and 160,000 Da, with pI values ranging between pH 4 and pH 4.4. In contrast, NaB[3H4]-labeled HL-60/AR cells showed 7–8 discrete glycoproteins within a molecular-weight range of 170,000 and 140,000 Da, with pI values also ranging between pH 4 and pH 4.4. In addition, [3H]-glucosamine incorporation into HL-60/S and HL-60/AR cells revealed that the latter showed lower uptake of [3H]-glucosamine than did the former. Following treatment with tunicamycin, [3H]-glucosamine uptake in HL-60/S cells decreased, whereas that in HL-60/AR cells remained unchanged. Surface-membrane radioiodination of HL-60/S and HL-60/AR cells showed two distinct protein electrophoretic patterns, with differences being observed in both the high-(220–95 kDa) and low-molecular-weight ranges (21 kDa). Flow cytometric analysis of HL-60/S and HL-60/AR cells using myeloid and lymphoid antigen-specific antibodies demonstrated no antigenic differences between HL-60/S and HL-60/AR cells. HL-60/S cells incubated in the presence of tunicamycin, an inhibitor ofN-linked glycosylation, or the protein kinase C agonist phorbol 12-myristate 13-acetate (PMA) developed a glycoprotein pattern similar to that observed in HL-60/AR cells. In addition, tunicamycin treatment of HL-60/S cells decreased daunorubicin (DNR) retention and altered its intracellular distribution as compared with that in HL-60/AR cells. These data indicate that HL-60/AR cells do not possess either de novo or amplified high-molecular-weight surface-membrane proteins; instead, existing proteins are hypoglycosylated. These results also show that HL-60/AR cells exhibit the multidrug-resistant phenotype in association with altered membrane glycoproteins of both high (220–95 kDa) and low molecular weight (21 kDa), but without overexpression of the P-glycoprotein. Furthermore, in HL-60/S cells, the multidrug-resistant phenotype is partially inducible by inhibition ofN-linked glycosylation of cell-surfac proteins.
Scandinavian Journal of Infectious Diseases | 2014
Anusiyanthan Mariampillai; Abirami Sivapiragasam; Amit Kumar; Alexander Hindenburg; Burke A. Cunha; Jianhong Zhou
Abstract We report the case of a patient with recurrent fever of unknown origin (FUO) with prominent back pain, hepatosplenomegaly, and abdominal/pelvic adenopathy suggesting lymphoma. A bone biopsy showed histiocytic infiltration. Studies for lymphoma were negative, but immunohistochemical stains were diagnostic of Erdheim–Chester disease (ECD). ECD should be included as a rare cause of recurrent FUO with bone involvement.
Journal of Clinical Oncology | 2018
Linda Phuong Hoang; Alexander Hindenburg
e18836Background: Despite data demonstrating an advantage of enoxaparin (LMWH) over heparin (UFH) for venous thromboembolism (VTE), an analysis of hospital prescribing trends showed use of each was...
Cancer Research | 1991
James E. Gervasoni; Scott Z. Fields; Sindu Krishna; Michael A. Baker; Michelle Rosado; Kalpna Thuraisamy; Alexander Hindenburg; Robert N. Taub
Cancer Research | 1987
Alexander Hindenburg; Michael A. Baker; Elizabeth Gleyzer; Valerie J. Stewart; Norris Case; Robert N. Taub
Blood | 1994
F Santiago-Schwarz; Dl Coppock; Alexander Hindenburg; J Kern
Blood | 1985
Michael A. Baker; Robert N. Taub; Kanani A; Brockhausen I; Alexander Hindenburg
Blood | 1984
Michael A. Baker; Robert N. Taub; Ch Whelton; Alexander Hindenburg
Cancer Research | 1985
Alexander Hindenburg; Robert N. Taub; Steven Grant; George J. Chang; Michael A. Baker